A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Acute Myeloid Leukemia
Age: Between 18 - 100 Years
Gender: Male or Female
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required